NASDAQ
KTRA

Kintara Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Kintara Therapeutics Inc Stock Price

Vitals

Today's Low:
$4.12
Today's High:
$4.62
Open Price:
$4.12
52W Low:
$2.7
52W High:
$15.5
Prev. Close:
$4.01
Volume:
3661

Company Statistics

Market Cap.:
$7.50 million
Book Value:
-4.054
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-108.16%
Return on Equity TTM:
-254.48%

Company Profile

Kintara Therapeutics Inc had its IPO on 2013-02-22 under the ticker symbol KTRA.

The company operates in the Healthcare sector and Biotechnology industry. Kintara Therapeutics Inc has a staff strength of 3 employees.

Stock update

Shares of Kintara Therapeutics Inc opened at $4.12 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $4.12 - $4.62, and closed at $4.22.

This is a +5.24% increase from the previous day's closing price.

A total volume of 3,661 shares were traded at the close of the day’s session.

In the last one week, shares of Kintara Therapeutics Inc have slipped by -4.74%.

Kintara Therapeutics Inc's Key Ratios

Kintara Therapeutics Inc has a market cap of $7.50 million, indicating a price to book ratio of 7.8075 and a price to sales ratio of 0.

In the last 12-months Kintara Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-16845000. The EBITDA ratio measures Kintara Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Kintara Therapeutics Inc’s operating margin was 0% while its return on assets stood at -108.16% with a return of equity of -254.48%.

In Q1, Kintara Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Kintara Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-14.08 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Kintara Therapeutics Inc’s profitability.

Kintara Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.8197. Its price to sales ratio in the trailing 12-months stood at 0.

Kintara Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$6.74 million
Total Liabilities
$2.79 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Kintara Therapeutics Inc ended 2024 with $6.74 million in total assets and $0 in total liabilities. Its intangible assets were valued at $6.74 million while shareholder equity stood at $3.79 million.

Kintara Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $2.79 million in other current liabilities, 2000.00 in common stock, $-148038000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $3.05 million and cash and short-term investments were $3.05 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Kintara Therapeutics Inc’s total current assets stands at $6.02 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $2.61 million and inventory worth $0.

In 2024, Kintara Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Kintara Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$4.22
52-Week High
$15.5
52-Week Low
$2.7
Analyst Target Price
$14

Kintara Therapeutics Inc stock is currently trading at $4.22 per share. It touched a 52-week high of $15.5 and a 52-week low of $15.5. Analysts tracking the stock have a 12-month average target price of $14.

Its 50-day moving average was $4.24 and 200-day moving average was $4.85 The short ratio stood at 1.17 indicating a short percent outstanding of 0%.

Around 416.7% of the company’s stock are held by insiders while 329.2% are held by institutions.

Frequently Asked Questions About Kintara Therapeutics Inc

The stock symbol (also called stock or share ticker) of Kintara Therapeutics Inc is KTRA

The IPO of Kintara Therapeutics Inc took place on 2013-02-22

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$778
-32.8
-4.05%
$15.76
0.1
+0.64%
$8.66
0.4
+4.84%
$145.95
-4.55
-3.02%
$261.6
-13.05
-4.75%
$125.75
-14.1
-10.08%
$165.95
-8.8
-5.04%
$177.02
-1.51
-0.85%
$0.85
-0.02
-2.74%
$14.21
-0.4
-2.71%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Address

9920 Pacific Heights Blvd, San Diego, CA, United States, 92121